Factors Associated With Semaglutide Initiation Among Adults With Obesity
Authors' conclusion
This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those without diabetes. These findings suggest that insurance plan type and structure may be a crucial intervention point for improving equity in obesity treatment access.
Study context
- Population
- US commercially insured adults aged ≥18 years with a first obesity diagnosis (June 5, 2021–July 1, 2022), no diagnosed diabetes, no prior antiobesity medication, GLP-1, bariatric surgery or diabetes-related claim in prior 12 months
- Participants
- 97,456 participants
- Outcome
- Factors associated with incident semaglutide prescription
- Follow-up
- Within 6 months after obesity diagnosis
Methodological detailsobservational, claims database (MarketScan), 10-fold cross-classified random forest model, multivariable logistic regression
- Observational
- Claims database (MarketScan)
- 10-fold cross-classified random forest model
- Multivariable logistic regression
Main finding
As reported in the abstract
Semaglutide initiation · within 6 months of initial obesity diagnosis
- Initiated semaglutide
- 1963 (2.0%)
- Random forest model AUC
- 0.71 (95% CI 0.69-0.74)
- Female sex, aOR
- 2.30 (95% CI 2.05-2.58)
- Use of antidepressants, aOR
- 1.62 (95% CI 1.46-1.78)
- Point-of-service plan coverage, aOR
- 1.78 (95% CI 1.42-2.22)
Observational data: associations, not effects.
Original publication
Factors Associated With Semaglutide Initiation Among Adults With Obesity. JAMA Netw Open. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →